Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics
Biomolecules · 07.05.2026 · 16 (5) · 690
DOI: 10.3390/biom16050690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 07.05.2026. Verfasst von Qiange Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou 310053, China. Hauptthemen laut MEDLINE: Flavobacteriaceae, Aspartylglucosylaminase, Bacterial Proteins, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Cooperation Project of Pingyang Traditional Chinese Medicine Hospital, Cooperation Project of Pingyang Traditional Chinese Medicine Hospital.
Abstract (Originalsprache)
Aspartylglucosaminidase (AGA) is an amidohydrolase that can hydrolyze the amide bond between N-acetylglucosamine (GlcNAc) and asparagine (Asn), producing N-acetylglucosamine and aspartic acid (Asp). AGA is distributed in both eukaryotes and prokaryotes. In this study, we identified the sequence of AGA in Elizabethkingia meningoseptica (EmAGA), cloned and expressed it in Escherichia coli, and recharacterized its properties, confirming its substrates as aspartylglucosamine (Asn-GlcNAc) and Asn. Key residues affecting its enzymatic activity were predicted through molecular docking and conserved site analysis, and 10 key residues that affected enzymatic activity were verified, eight of which regulated activity by interfering with EmAGA’s autoproteolysis, indicating that autoproteolytic cleavage into α/β subunits was essential for EmAGA maturation. Molecular dynamics simulations were performed on autohydrolysis-impaired mutants, which showed a more stable conformation and lower energy. In summary, EmAGA’s functional characterization provided novel evidence for elucidating its molecular mechanism. Clinically used Asparaginase (ASNase) exerts its therapeutic effect on acute lymphoblastic leukemia (ALL) through its asparaginase activity, but it is limited by glutamine off-target side effects, while EmAGA also has asparaginase activity but no glutaminase activity, rendering its potential as a basis for novel anti-leukemic enzymatic therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou 310053, China.
- Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Förderung
- the Cooperation Project of Pingyang Traditional Chinese Medicine Hospital
- Cooperation Project of Pingyang Traditional Chinese Medicine Hospital
Zitieren
APA
Lin, Q., Zhang, Y., Lin, J., Ye, Y., Qian, X., Lu, X., Lyu, S., Geng, X., Chen, L., & Sun, G. (2026). Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics. Biomolecules, 16(5), 690. https://doi.org/10.3390/biom16050690
Vancouver
Lin Q, Zhang Y, Lin J, Ye Y, Qian X, Lu X, et al. Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics. Biomolecules. 2026;16(5):690. doi:10.3390/biom16050690
BibTeX
@article{Lin2026,
author = {Lin, Qiange and Zhang, Yuxin and Lin, Junyou and Ye, Yilin and Qian, Xin and Lu, Xinrong and Lyu, Shaoxian and Geng, Xinliu and Chen, Li and Sun, Guiqin},
title = {Recharacterization of EmAGA, a Potential Candidate for Novel ALL Therapeutics},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {5},
pages = {690},
doi = {10.3390/biom16050690}
}
EUVIMED